A detailed history of Sargent Investment Group, LLC transactions in Exelixis, Inc. stock. As of the latest transaction made, Sargent Investment Group, LLC holds 232,245 shares of EXEL stock, worth $8 Million. This represents 1.1% of its overall portfolio holdings.

Number of Shares
232,245
Previous 242,895 4.38%
Holding current value
$8 Million
Previous $5.46 Million 10.43%
% of portfolio
1.1%
Previous 1.13%

Shares

25 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 06, 2024

SELL
$21.96 - $27.6 $233,874 - $293,940
-10,650 Reduced 4.38%
232,245 $6.03 Million
Q2 2024

Aug 09, 2024

SELL
$20.34 - $23.73 $723,595 - $844,194
-35,575 Reduced 12.78%
242,895 $5.46 Million
Q1 2024

May 10, 2024

SELL
$20.17 - $23.93 $360,639 - $427,868
-17,880 Reduced 6.03%
278,470 $6.61 Million
Q4 2023

Feb 05, 2024

SELL
$19.25 - $24.13 $31,666 - $39,693
-1,645 Reduced 0.55%
296,350 $7.11 Million
Q3 2023

Nov 13, 2023

SELL
$19.04 - $22.74 $115,382 - $137,804
-6,060 Reduced 1.99%
297,995 $6.51 Million
Q2 2023

Jul 31, 2023

SELL
$18.17 - $20.48 $170,798 - $192,512
-9,400 Reduced 3.0%
304,055 $5.81 Million
Q1 2023

May 02, 2023

BUY
$16.3 - $19.41 $374,818 - $446,332
22,995 Added 7.92%
313,455 $6.08 Million
Q4 2022

Jan 31, 2023

BUY
$14.96 - $17.39 $113,696 - $132,164
7,600 Added 2.69%
290,460 $4.66 Million
Q3 2022

Oct 26, 2022

BUY
$15.68 - $22.27 $332,024 - $471,567
21,175 Added 8.09%
282,860 $4.41 Million
Q2 2022

Jul 26, 2022

BUY
$17.44 - $23.16 $461,026 - $612,234
26,435 Added 11.24%
261,685 $5.45 Million
Q1 2022

May 06, 2022

SELL
$17.03 - $22.67 $1.04 Million - $1.39 Million
-61,170 Reduced 20.64%
235,250 $5.33 Million
Q4 2021

Feb 11, 2022

BUY
$15.84 - $21.88 $1.38 Million - $1.9 Million
86,850 Added 41.44%
296,420 $5.42 Million
Q3 2021

Nov 12, 2021

SELL
$16.3 - $21.14 $4.48 Million - $5.81 Million
-274,850 Reduced 56.74%
209,570 $4.43 Million
Q2 2021

Aug 05, 2021

SELL
$17.95 - $25.56 $250,043 - $356,050
-13,930 Reduced 2.8%
484,420 $8.83 Million
Q1 2021

May 04, 2021

BUY
$20.53 - $25.22 $607,585 - $746,385
29,595 Added 6.31%
498,350 $11.3 Million
Q4 2020

Feb 10, 2021

SELL
$18.39 - $24.8 $1.04 Million - $1.4 Million
-56,330 Reduced 10.73%
468,755 $9.41 Million
Q3 2020

Nov 12, 2020

SELL
$20.67 - $26.94 $91,774 - $119,613
-4,440 Reduced 0.84%
525,085 $12.8 Million
Q2 2020

Aug 11, 2020

SELL
$16.46 - $27.42 $778,228 - $1.3 Million
-47,280 Reduced 8.2%
529,525 $12.4 Million
Q1 2020

May 12, 2020

BUY
$14.46 - $21.8 $672,751 - $1.01 Million
46,525 Added 8.77%
576,805 $9.93 Million
Q4 2019

Feb 11, 2020

BUY
$15.15 - $18.89 $424,200 - $528,920
28,000 Added 5.57%
530,280 $9.34 Million
Q4 2019

Jan 30, 2020

BUY
$15.15 - $18.89 $555,399 - $692,507
36,660 Added 7.87%
502,280 $8.85 Million
Q3 2019

Oct 29, 2019

BUY
$17.68 - $22.65 $592,191 - $758,661
33,495 Added 7.75%
465,620 $8.23 Million
Q2 2019

Aug 12, 2019

BUY
$18.93 - $24.75 $31,897 - $41,703
1,685 Added 0.39%
432,125 $9.24 Million
Q1 2019

May 13, 2019

BUY
$19.6 - $24.76 $709,324 - $896,064
36,190 Added 9.18%
430,440 $10.2 Million
Q4 2018

Feb 12, 2019

BUY
$13.65 - $21.8 $5.38 Million - $8.59 Million
394,250 New
394,250 $7.76 Million

Others Institutions Holding EXEL

About EXELIXIS, INC.


  • Ticker EXEL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 321,832,000
  • Market Cap $11.1B
  • Description
  • Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ ...
More about EXEL
Track This Portfolio

Track Sargent Investment Group, LLC Portfolio

Follow Sargent Investment Group, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Sargent Investment Group, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Sargent Investment Group, LLC with notifications on news.